Real-world evidence (RWE) shows that HIV-associated wasting (HIVAW) remains a significant comorbidity

• A first retrospective, RWE study investigating HIVAW in more than 10 years suggests the condition remains a significant comorbidity despite modern antiretroviral therapy (ART).
• Results showed the overall prevalence of HIVAW in the study of 42,587 HIV+ patients was 18.3%.
• “Many physicians consider HIV-associated wasting no longer an existing comorbidity in the era of modern ART, but the evidence suggests otherwise and the continued need for on-going assessments of people living with HIV for weight loss,”

Javeed Siddiqui

MD, MPH

Chief Medical Officer of TeleMed2U

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref: RWEAPR2022CWA